Andrew Betts

The Global Antibiotic Research and Development Partnership, North America (GARDP NA) is pleased to welcome Andrew Betts as its new Executive Director. Andy joins GARDP NA from the PKD Foundation based in Kansas City, MO, where he served as its President and CEO. During his tenure, the foundation was instrumental in helping to secure the first biomarker and FDA-approved treatment for a vastly unknown disease and they accomplished the largest advocacy effort for public funding in the foundation’s history.  

In addition, Andy also raised an additional $70M from private funds, which grew their net assets by 510%, increased revenue by 67%, and led to a 300% growth in all programs. 

Prior to this role, Andy served as the Executive Director for Development at The Salvation Army, Kansas & Missouri, overseeing all the development and marketing teams across 28 cities and achieving annual revenues of $50M+.

In his new role as Executive Director at GARDP NA, Andy will build the presence and profile of GARDP NA in tackling antibiotic resistance, one of the biggest health threats in North America and globally. He will work closely with the GARDP network with the common purpose of raising awareness and developing solutions to tackle antibiotic resistance worldwide.  Andy will report directly to the GARDP NA Board.

The GARDP NA press release can be found here – https://gardpna.org/gardp-north-america-appoints-new-executive-director/

About GARDP NA

Founded in 2021, GARDP NA, registered under the legal name GARDP North America Inc., drives innovative solutions to antibiotic resistance, one of the biggest health threats in North America and globally. As a member of the Global Antibiotic Research and Development Partnership’s network, GARDP NA pursues the common goal of accelerating the development and availability of much-needed antibiotic treatments. GARDP NA operates    independently with its own Board.

Founded in 2021, GARDP NA, registered under the legal name GARDP North America Inc., drives innovative solutions to antibiotic resistance, one of the biggest health threats in North America and globally. As a member of the Global Antibiotic Research and Development Partnership’s network, GARDP NA pursues the common goal of accelerating the development and availability of much-needed antibiotic treatments. GARDP NA operates independently with its own governing Board and received IRS 501(c)(3) status within the United States in May 2022.

For more information about GARDP NA, please visit gardpna.org.